OBJECTIVE: To determine adherence to guidelines for severe asthma care and evaluate regional variability in practice among pediatric intensive care units (PICU). STUDY DESIGN: A retrospective cohort study of children treated for asthma in a PICU during 2000 to 2003. We utilized the Pediatric Health Information System (PHIS) database to identify patients and determine use of asthma therapies when patients did not improve with standard therapy (inhaled beta-agonists and systemic corticosteroids). RESULTS: Of 7125 children studied, 59% received inhaled anticholinergic medications. Use of other therapies included systemic beta-agonists (n = 1841 [26%]), magnesium sulfate (n = 1521 [21%]), methylxanthines (n = 426 [6%]), inhaled helium-oxygen gas mixture (heliox) (n = 740 [10%]), and endotracheal intubation with ventilation (n=1024 [14%]). Use of therapies varied by census region. Over half the patients (n = 524) who received ventilation did so for < or = 1 day. Adjusted for severity of illness, use of mechanical ventilation varied significantly by census division; however, much of the variation was among children ventilated for < or = 1 day. CONCLUSION: Adherence to national guidelines for use of inhaled anticholinergics among critically ill children is low, and marked variation in use of invasive ventilation exists. More explicit guidelines regarding indications for invasive ventilation may improve asthma care.
OBJECTIVE: To determine adherence to guidelines for severe asthma care and evaluate regional variability in practice among pediatric intensive care units (PICU). STUDY DESIGN: A retrospective cohort study of children treated for asthma in a PICU during 2000 to 2003. We utilized the Pediatric Health Information System (PHIS) database to identify patients and determine use of asthma therapies when patients did not improve with standard therapy (inhaled beta-agonists and systemic corticosteroids). RESULTS: Of 7125 children studied, 59% received inhaled anticholinergic medications. Use of other therapies included systemic beta-agonists (n = 1841 [26%]), magnesium sulfate (n = 1521 [21%]), methylxanthines (n = 426 [6%]), inhaled helium-oxygen gas mixture (heliox) (n = 740 [10%]), and endotracheal intubation with ventilation (n=1024 [14%]). Use of therapies varied by census region. Over half the patients (n = 524) who received ventilation did so for < or = 1 day. Adjusted for severity of illness, use of mechanical ventilation varied significantly by census division; however, much of the variation was among children ventilated for < or = 1 day. CONCLUSION: Adherence to national guidelines for use of inhaled anticholinergics among critically ill children is low, and marked variation in use of invasive ventilation exists. More explicit guidelines regarding indications for invasive ventilation may improve asthma care.
Authors: Meredith A Dilley; William J Sheehan; Carter R Petty; Jonathan M Gaffin; Marissa Hauptman; Wanda Phipatanakul Journal: J Allergy Clin Immunol Pract Date: 2016-11-23
Authors: Ben G McGahan; Beth K Neilsen; David L Kelly; Rodney D McComb; S A Jaffar Kazmi; Matt L White; Yan Zhang; Michele R Aizenberg Journal: J Neurooncol Date: 2017-01-19 Impact factor: 4.130
Authors: Abdallah R Dalabih; Steven A Bondi; Zena L Harris; Benjamin R Saville; Wenli Wang; Donald H Arnold Journal: Pulm Pharmacol Ther Date: 2013-03-19 Impact factor: 3.410
Authors: Christopher J L Newth; Kathleen L Meert; Amy E Clark; Frank W Moler; Athena F Zuppa; Robert A Berg; Murray M Pollack; Katherine A Sward; John T Berger; David L Wessel; Rick E Harrison; Jean Reardon; Joseph A Carcillo; Thomas P Shanley; Richard Holubkov; J Michael Dean; Allan Doctor; Carol E Nicholson Journal: J Pediatr Date: 2012-04-10 Impact factor: 4.406
Authors: Susan L Bratton; Christopher J L Newth; Athena F Zuppa; Frank W Moler; Kathleen L Meert; Robert A Berg; John Berger; David Wessel; Murray Pollack; Rick Harrison; Joseph A Carcillo; Thomas P Shanley; Teresa Liu; Richard Holubkov; J Michael Dean; Carol E Nicholson Journal: Pediatr Crit Care Med Date: 2012-07 Impact factor: 3.624